Glimsay M1 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The prolonged-release formulation of Glimsay M1 Forte ensures a steady plasma concentration, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. This combination is particularly beneficial for patients inadequately controlled on monotherapy or those requiring dual mechanism action to achieve target glycemic levels. Glimsay M1 Forte should be administered under medical supervision, with dosage adjustments based on glycemic response and renal function monitoring, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Patients should be counseled on lifestyle modifications, adherence to therapy, and recognition of hypoglycemia symptoms. Regular monitoring of blood glucose and HbA1c is essential to optimize therapeutic outcomes with Glimsay M1 Forte Tablet PR.